Grace Therapeutics Inc. Ordinary Shares GRCE 深 沪
已收盘 09-26 16:00:00 美东时间
3.09
+0.010
+0.32%
华盛通- 最 高3.106
- 今 开3.07
- 成交量 2.91万股
- 最 低 3.0403
- 昨 收 3.08
- 总市值 3133.23万
- 52周最高 4.965
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 1.75
- 委 比 -7.41%
- 总股本 1013.99万
- 历史最高 2016.00
- 量 比 0.48
- 振 幅 2.13%
- 历史最低 1.75
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
Grace Therapeutics announced positive results from its Phase 3 STRIVE-ON trial for GTx-104, an intravenous nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The trial showed GTx-104 is safe, reduces hypotension compared to oral nimodipine, and improves ICU outcomes. The FDA has accepted the NDA for review with a decision targeted by April 2026. The company highlights GTx-104's potential as a significant innovation for...
09-22 12:00
Grace Therapeutics Secures New Patent for GTx-104
An update from Grace Therapeutics ( ($GRCE) ) is now available. On September 18...
09-18 20:58
Grace Therapeutics Awarded Patent Titled "Nimodipine Parenteral Administration" From U.S. Patent and Trademark Office. Patent Covers Dosing Regimen For Intravenous Nimodipine Used In Phase 3 Strive-On Safety Trial For GTX-104
Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V.
09-18 20:38
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Grace Therapeutics获得美国专利号12,414,943，涉及尼莫地平的静脉给药方案，专利有效期至2043年。该专利加强了GTx-104的知识产权保护，结合其孤儿药指定带来的7年市场独占权，进一步巩固了其市场地位。STRIVE-ON试验显示，GTx-104在安全性及疗效方面优于口服尼莫地平，为公司未来商业价值及股东回报提供有力支持。
09-18 12:30
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Grace Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8–10, 2025. The event will take place at the Lotte New York Palace Hotel with virtual participation available. Prashant Kohli, CEO, will meet with institutional investors. Grace Therapeutics is a late-stage biopharma company advancing GTx-104, an IV formulation of nimodipine targeting aSAH, a rare and life-threatening condition. GTx-104 ha...
09-04 12:00
FDA Accepts Grace Therapeutics’ NDA for GTx-104
Grace Therapeutics ( ($GRCE) ) has issued an update. On August 22, 2025, the FD...
08-27 20:29
FDA Accepts Grace Therapeutics' New Drug Administration For GTx-104 For Formal Review
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Supported by
08-27 20:03
Grace Therapeutics Q1 EPS $(0.21) Beats $(0.22) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4.55 percent.
08-12 20:07
Grace Therapeutics Submits NDA To FDA For GTx-104; Submission Seeks Approval Of GTx-104 In Treatment Of Patients With Aneurysmal Subarachnoid Hemorrhage
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of
06-25 20:02
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Grace Therapeutics submitted its New Drug Application (NDA) to the FDA for GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The application includes positive results from the Phase 3 STRIVE-ON safety trial, which showed GTx-104 met its primary endpoint with a 19% reduction in clinically significant hypotension compared to oral nimodipine. The submission could trigger up to $7.6 million in warra...
06-25 12:00
